Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Based in Horsholm, Denmark, ExpreS2ion Biotech Holding AB, along with its subsidiary ExpreS2ion Biotechnologies, specializes in creating and manufacturing complex proteins for use in vaccines and diagnostic products. The company's development pipeline includes a capsid virus-like particle COVID-19 vaccine, an influenza vaccine, and a breast cancer vaccine, all of which are currently undergoing Phase II clinical trials. ExpreS2ion is also engaged in developing a malaria vaccine. Furthermore, the company extends its reach by licensing its proprietary ExpreS2 platform to various research organizations and pharmaceutical businesses. ExpreS2ion Biotech Holding AB commenced operations in 2015.
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. Specifically, the stock is undervalued on EV/EBITDA.